IL1B and non-small cell lung carcinoma: The CANOPY-A trial (NCT03447769) evaluated the anti-Interleukin-1 beta (IL-1β) monoclonal antibody canakinumab post-chemotherapy in patients with stage II–IIIB NSCLC, aiming to exploit inflammatory pathways as therapeutic targets.